These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 35116092)

  • 41. Crosstalk Between Peroxisome Proliferator-Activated Receptor Gamma and the Canonical WNT/β-Catenin Pathway in Chronic Inflammation and Oxidative Stress During Carcinogenesis.
    Vallée A; Lecarpentier Y
    Front Immunol; 2018; 9():745. PubMed ID: 29706964
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden.
    Voskaridou E; Komninaka V; Karavas A; Terpos E; Akianidis V; Christoulas D
    Transfusion; 2014 Mar; 54(3):646-9. PubMed ID: 23834310
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease.
    Marsella M; Borgna-Pignatti C
    Hematol Oncol Clin North Am; 2014 Aug; 28(4):703-27, vi. PubMed ID: 25064709
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
    Kontoghiorghes GJ; Kolnagou A
    Haematologica; 2006 Jun; 91(6 Suppl):ELT04. PubMed ID: 16785141
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Iron Metabolism in Aging and Age-Related Diseases.
    Tian Y; Tian Y; Yuan Z; Zeng Y; Wang S; Fan X; Yang D; Yang M
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408967
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.
    Porter JB; Elalfy MS; Taher AT; Aydinok Y; Chan LL; Lee SH; Sutcharitchan P; Habr D; Martin N; El-Beshlawy A
    Ann Hematol; 2013 Jan; 92(2):211-9. PubMed ID: 23086508
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New developments in iron chelators.
    Cunningham MJ; Nathan DG
    Curr Opin Hematol; 2005 Mar; 12(2):129-34. PubMed ID: 15725903
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative study of the protective effect between deferoxamine and deferiprone on chronic iron overload induced cardiotoxicity in rats.
    Emara AM; El Kelany RS; Moustafa KA
    Hum Exp Toxicol; 2006 Jul; 25(7):375-85. PubMed ID: 16898166
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation and treatment of transfusional iron overload in children.
    Ware HM; Kwiatkowski JL
    Pediatr Clin North Am; 2013 Dec; 60(6):1393-406. PubMed ID: 24237978
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Activation of the molecular and functional effects of Nrf2 against chronic iron oxide nanorod overload-induced cardiotoxicity.
    Elgharabawy RM; Elgharbawy DM; Emara AM
    Hum Exp Toxicol; 2018 Aug; 37(8):870-885. PubMed ID: 29172713
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intracellular iron overload leading to DNA damage of lymphocytes and immune dysfunction in thalassemia major patients.
    Shaw J; Chakraborty A; Nag A; Chattopadyay A; Dasgupta AK; Bhattacharyya M
    Eur J Haematol; 2017 Nov; 99(5):399-408. PubMed ID: 28815805
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Iron overload in thalassemia: different organs at different rates.
    Taher AT; Saliba AN
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):265-271. PubMed ID: 29222265
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Monitoring and treatment of iron overload: state of the art and new approaches.
    Porter JB
    Semin Hematol; 2005 Apr; 42(2 Suppl 1):S14-8. PubMed ID: 15846580
    [No Abstract]   [Full Text] [Related]  

  • 54. Diagnosis and treatment of cardiac iron overload in transfusion-dependent thalassemia patients.
    Siri-Angkul N; Chattipakorn SC; Chattipakorn N
    Expert Rev Hematol; 2018 Jun; 11(6):471-479. PubMed ID: 29754517
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Thalassemia: cardiac iron and chelators.
    Gaur A
    Indian Pediatr; 2012 Apr; 49(4):268-9. PubMed ID: 22565070
    [No Abstract]   [Full Text] [Related]  

  • 56. Deferasirox for managing iron overload in people with myelodysplastic syndrome.
    Meerpohl JJ; Antes G; Rücker G; Fleeman N; Motschall E; Niemeyer CM; Bassler D
    Cochrane Database Syst Rev; 2010 Nov; (11):CD007461. PubMed ID: 21069694
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Combined Iron Chelator and Antioxidant Exerted Greater Efficacy on Cardioprotection Than Monotherapy in Iron-Overloaded Rats.
    Wongjaikam S; Kumfu S; Khamseekaew J; Sripetchwandee J; Srichairatanakool S; Fucharoen S; Chattipakorn SC; Chattipakorn N
    PLoS One; 2016; 11(7):e0159414. PubMed ID: 27428732
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
    Vichinsky E; Onyekwere O; Porter J; Swerdlow P; Eckman J; Lane P; Files B; Hassell K; Kelly P; Wilson F; Bernaudin F; Forni GL; Okpala I; Ressayre-Djaffer C; Alberti D; Holland J; Marks P; Fung E; Fischer R; Mueller BU; Coates T;
    Br J Haematol; 2007 Feb; 136(3):501-8. PubMed ID: 17233848
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.
    Fisher SA; Brunskill SJ; Doree C; Gooding S; Chowdhury O; Roberts DJ
    Cochrane Database Syst Rev; 2013 Aug; (8):CD004450. PubMed ID: 23963793
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mice lacking liver-specific β-catenin develop steatohepatitis and fibrosis after iron overload.
    Preziosi ME; Singh S; Valore EV; Jung G; Popovic B; Poddar M; Nagarajan S; Ganz T; Monga SP
    J Hepatol; 2017 Aug; 67(2):360-369. PubMed ID: 28341391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.